A Single-center Open-label Phase I Study of ALT-801 for ex vivo Maturation and in vivo Retargeting of Haploidentical Natural Killer Cells Delivered Following Fludarabine, Cytarabine, and G-CSF in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Trial Profile

A Single-center Open-label Phase I Study of ALT-801 for ex vivo Maturation and in vivo Retargeting of Haploidentical Natural Killer Cells Delivered Following Fludarabine, Cytarabine, and G-CSF in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2014

At a glance

  • Drugs ALT 801 (Primary) ; Cytarabine; Fludarabine; Lymphokine-activated killer cells
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Altor BioScience Corporation
  • Most Recent Events

    • 24 Nov 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by M.D. Anderson Cancer Center.
    • 25 Nov 2011 Actual trial start date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 25 Nov 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top